Literature DB >> 18423915

MDM2 SNP 309 and p53 codon 72 polymorphisms are associated with the outcome of oral carcinoma patients receiving postoperative irradiation.

Hsi-Feng Tu1, Hong-Wen Chen, Shou-Yen Kao, Shu-Chun Lin, Chung-Ji Liu, Kuo-Wei Chang.   

Abstract

BACKGROUND AND
PURPOSE: The p53 tumor suppression pathway is important in effects associated with radiotherapy. The mouse double minute 2 (MDM2) plays a pivotal role in this pathway by down regulating p53. A functional T-to-G polymorphism at nucleotide 309 in MDM2 promoter intron 1 (SNP309) has been identified which influenced transcription activity. A G-to-C SNP at p53 codon 72 results in an Arg/Pro polymorphism, which is associated with apoptosis induction potential and p53 mutation status.
MATERIALS AND METHODS: We sequenced both MDM2 SNP309 and p53 codon 72 SNP in patients with oral squamous cell carcinoma (OSCC, n=189), oral submucosal fibrosis (OSF, n=70), and 116 controls.
RESULTS: Neither MDM2 SNP309 nor p53 codon 72 SNP was associated with susceptibility to or the age at onset of OSCC or OSF. p53 codon 72 SNP Arg/Arg polymorphism was associated with the progression of OSCC, and the overall (OS) and disease-free survival (DFS) of irradiated patients. The MDM2 SNP309 G/G polymorphism was associated with poor OS in advanced OSCC, and the OS and DSF of irradiated patients. The combination of MDM2 SNP309 G/G and p53 codon 72 Arg/Arg polymorphism is associated with the worst OS and DFS.
CONCLUSIONS: Advanced OSCC has high mortality and recurrence. We identified that both MDM2 SNP309 and p53 codon 72 SNP could be useful factors for evaluating the outcome of advanced OSCC treated with adjuvant radiation.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18423915     DOI: 10.1016/j.radonc.2008.03.018

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  19 in total

Review 1.  New biological markers in the decision of treatment of head and neck cancer patients.

Authors:  A Valenciano; L A Henríquez-Hernández; M Lloret; B Pinar; P C Lara
Journal:  Clin Transl Oncol       Date:  2014-07-01       Impact factor: 3.405

2.  No significant association between p53 codon 72 Arg/Pro polymorphism and risk of oral cancer.

Authors:  Ning Jiang; Jie Pan; Lei Wang; Yin-Zhong Duan
Journal:  Tumour Biol       Date:  2012-11-29

3.  Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects.

Authors:  X I Yang; Yun Zhu; Dongxia Ye; Yang Liu; Hongying Sun; Min Ruan; Wei Liu
Journal:  Mol Clin Oncol       Date:  2016-04-20

4.  Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.

Authors:  Hongping Yu; Yu-jing Huang; Zhensheng Liu; Li-E Wang; Guojun Li; Erich M Sturgis; David G Johnson; Qingyi Wei
Journal:  Mol Carcinog       Date:  2011-06-07       Impact factor: 4.784

5.  MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group.

Authors:  Christine L Phillips; Robert Gerbing; Todd Alonzo; John P Perentesis; Isaac T W Harley; Soheil Meshinchi; Deepika Bhatla; Gretchen Radloff; Stella M Davies
Journal:  Pediatr Blood Cancer       Date:  2010-08       Impact factor: 3.167

6.  Differences in the expression of five senescence markers in oral cancer, oral leukoplakia and control samples in humans.

Authors:  Antonio Bascones-Martínez; Mercedes López-Durán; Jorge Cano-Sánchez; Lydia Sánchez-Verde; Ana Díez-Rodríguez; Pablo Aguirre-Echebarría; Emilio Alvarez-Fernández; Miguel Angel González-Moles; Jaime Bascones-Ilundain; Lorenzo Lo Muzio; Julián Campo-Trapero
Journal:  Oncol Lett       Date:  2012-03-19       Impact factor: 2.967

7.  Identification of SNPs associated with susceptibility for development of adverse reactions to radiotherapy.

Authors:  Barry S Rosenstein
Journal:  Pharmacogenomics       Date:  2011-02       Impact factor: 2.533

Review 8.  Genotypic distribution of single nucleotide polymorphisms in oral cancer: global scene.

Authors:  Shaleen Multani; Dhananjaya Saranath
Journal:  Tumour Biol       Date:  2016-09-20

Review 9.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

10.  No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.

Authors:  Jerry J Jaboin; Misun Hwang; Carmen A Perez; Calvin Cooper; Heidi Chen; Chuanzhong Ye; Qiuyin Cai; Marcia L Wills; Bo Lu
Journal:  Urol Oncol       Date:  2009-06-12       Impact factor: 3.498

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.